Skip to content
Biodatica
Start free

Daiichi Sankyo

Duarte, California

OncologyPhase IIIListed · DSNKY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

1w agoTrial registeredJul 6, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Oct 24, 2024

    Healthy Subjects · COMPLETED · sponsor: Daiichi Sankyo · A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate

    ClinicalTrials.gov · NCT06772246 (opens the source filing in a new tab)

  2. Trial

    PHASE2/PHASE3 registered

    Feb 27, 2024

    Solid Cancer · RECRUITING · sponsor: Daiichi Sankyo · A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    ClinicalTrials.gov · NCT06161025 (opens the source filing in a new tab)

  3. Trial

    PHASE1/PHASE2 registered

    Jun 7, 2023

    Systemic Lupus Erythematosus · COMPLETED · sponsor: Daiichi Sankyo · A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

    ClinicalTrials.gov · NCT05638802 (opens the source filing in a new tab)

  4. Trial

    Study registered

    Feb 16, 2023

    Atrial Fibrillation · COMPLETED · sponsor: Daiichi Sankyo · A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation

    ClinicalTrials.gov · NCT05804747 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    Jan 11, 2023

    Metastatic Non Small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Daiichi Sankyo · Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

    ClinicalTrials.gov · NCT05555732 (opens the source filing in a new tab)

  6. Trial

    Study registered

    Aug 10, 2021

    Dyslipidemia · COMPLETED · sponsor: Daiichi Sankyo · An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia

    ClinicalTrials.gov · NCT05120895 (opens the source filing in a new tab)

  7. Trial

    PHASE2 registered

    Jun 3, 2021

    Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Daiichi Sankyo · Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

    ClinicalTrials.gov · NCT04703192 (opens the source filing in a new tab)

  8. Trial

    Study registered

    Feb 26, 2021

    Non-valvular Atrial Fibrillation · COMPLETED · sponsor: Daiichi Sankyo · Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

    ClinicalTrials.gov · NCT04747496 (opens the source filing in a new tab)

  9. Trial

    PHASE2 registered

    Nov 26, 2019

    Adenocarcinoma Gastric Stage IV With Metastases, Adenocarcinoma - GEJ · COMPLETED · sponsor: Daiichi Sankyo · DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

    ClinicalTrials.gov · NCT04014075 (opens the source filing in a new tab)

  10. Trial

    PHASE1/PHASE2 registered

    Aug 15, 2018

    Acute Myeloid Leukemia · ACTIVE_NOT_RECRUITING · sponsor: Daiichi Sankyo · Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

    ClinicalTrials.gov · NCT03793478 (opens the source filing in a new tab)

  11. Trial

    PHASE3 registered

    Aug 9, 2018

    Breast Cancer · ACTIVE_NOT_RECRUITING · sponsor: Daiichi Sankyo · DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

    ClinicalTrials.gov · NCT03529110 (opens the source filing in a new tab)

  12. Trial

    NA registered

    Jan 31, 2017

    Melanoma · COMPLETED · sponsor: Daiichi Sankyo Co., Ltd. · A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma

    ClinicalTrials.gov · NCT02975700 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources